Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Short Interest Down 22.0% in April

Syros Pharmaceuticals, Inc. (NASDAQ:SYRSGet Free Report) saw a large decrease in short interest in April. As of April 30th, there was short interest totalling 1,450,000 shares, a decrease of 22.0% from the April 15th total of 1,860,000 shares. Based on an average daily trading volume, of 196,500 shares, the days-to-cover ratio is currently 7.4 days. Currently, 7.8% of the shares of the stock are sold short.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the company. Piper Sandler reiterated an “overweight” rating and issued a $13.00 price objective on shares of Syros Pharmaceuticals in a research note on Wednesday, April 3rd. HC Wainwright reiterated a “buy” rating and issued a $15.00 price target on shares of Syros Pharmaceuticals in a research report on Monday, April 1st. Finally, StockNews.com cut Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, April 17th.

Check Out Our Latest Report on Syros Pharmaceuticals

Institutional Investors Weigh In On Syros Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the company. Assenagon Asset Management S.A. lifted its stake in shares of Syros Pharmaceuticals by 142.2% in the 3rd quarter. Assenagon Asset Management S.A. now owns 25,130 shares of the company’s stock valued at $99,000 after purchasing an additional 14,754 shares during the period. Acadian Asset Management LLC acquired a new position in Syros Pharmaceuticals in the first quarter valued at about $91,000. Avidity Partners Management LP boosted its holdings in Syros Pharmaceuticals by 5.8% during the fourth quarter. Avidity Partners Management LP now owns 1,673,538 shares of the company’s stock worth $13,037,000 after buying an additional 92,396 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Syros Pharmaceuticals by 21.3% in the 1st quarter. Vanguard Group Inc. now owns 928,046 shares of the company’s stock valued at $4,965,000 after acquiring an additional 163,234 shares during the last quarter. Finally, Flagship Pioneering Inc. raised its position in shares of Syros Pharmaceuticals by 30.2% in the 4th quarter. Flagship Pioneering Inc. now owns 1,293,848 shares of the company’s stock valued at $10,079,000 after acquiring an additional 300,000 shares during the period. 91.47% of the stock is owned by institutional investors and hedge funds.

Syros Pharmaceuticals Price Performance

Syros Pharmaceuticals stock traded up $0.37 on Tuesday, reaching $5.43. The company’s stock had a trading volume of 187,271 shares, compared to its average volume of 200,804. The business’s fifty day moving average price is $5.53 and its 200 day moving average price is $5.54. The company has a debt-to-equity ratio of 2.07, a quick ratio of 3.95 and a current ratio of 3.95. Syros Pharmaceuticals has a twelve month low of $2.09 and a twelve month high of $8.17. The company has a market cap of $145.13 million, a price-to-earnings ratio of -0.94 and a beta of 1.75.

Syros Pharmaceuticals (NASDAQ:SYRSGet Free Report) last posted its quarterly earnings data on Wednesday, March 27th. The company reported ($1.19) earnings per share for the quarter, beating the consensus estimate of ($1.23) by $0.04. Syros Pharmaceuticals had a negative net margin of 1,656.34% and a negative return on equity of 227.91%. The firm had revenue of $0.39 million during the quarter, compared to analysts’ expectations of $2.40 million. Equities analysts expect that Syros Pharmaceuticals will post -3.78 earnings per share for the current fiscal year.

Syros Pharmaceuticals Company Profile

(Get Free Report)

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.

Featured Articles

Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.